As of the latest Form 4 filed Jun 5, 2026.
What Catalyst Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 38 most recent filings for CPRX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | 2026-06-03 | Andrews William T. Chief Medical Officer | FTax | −743.00 | — | — | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Andrews William T., Chief Medical Officer | MExercise | +3.05K | — | — | No | Form 4 ↗ |
| 2026-02-19 | 2026-02-17 | Russo Gregg Chief HR Officer | FTax | −211.00 | — | — | No | Form 4 ↗ |
| 2026-02-19 | 2026-02-17 | Russo Gregg, Chief HR Officer | MExercise | +687.00 | — | — | No | Form 4 ↗ |
| 2026-01-06 | 2026-01-05 | Kalb Michael Wayne Executive Vice President & CFO | FTax | −2.08K | — | — | No | Form 4 ↗ |
| 2026-01-06 | 2026-01-05 | Kalb Michael Wayne, Executive Vice President & CFO | MExercise | +7.14K | — | — | No | Form 4 ↗ |
| 2026-01-06 | 2026-01-05 | Daly Richard J President and CEO | FTax | −10.6K | — | — | No | Form 4 ↗ |
| 2026-01-06 | 2026-01-05 | Daly Richard J, President and CEO | MExercise | +42.1K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Tierney David S Director | MExercise | +1.33K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Sundaram Preethi Chief Strategy Officer | FTax | −2.37K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Sundaram Preethi, Chief Strategy Officer | MExercise | +6.67K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Miller Steve Chief Op. & Scientific Officer | MExercise | +14.0K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | MCENANY PATRICK J Director | FTax | −6.79K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | MCENANY PATRICK J, Director | MExercise | +26.3K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Harper Molly Director | MExercise | +1.33K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Elsbernd Brian Chief Compliance/Legal Officer | FTax | −2.62K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Elsbernd Brian, Chief Compliance/Legal Officer | MExercise | +6.67K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | DENKHAUS DONALD A Director | MExercise | +1.33K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Del Carmen Jeffrey Chief Commercial Officer | FTax | −3.84K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Del Carmen Jeffrey, Chief Commercial Officer | MExercise | +8.67K | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Daly Richard J President and CEO | FTax | −524.00 | — | — | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Daly Richard J, President and CEO | MExercise | +1.33K | — | — | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Harper Molly Director | SSale | −6.75K | $23.06 | $156K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Harper Molly, Director | SSale | −4.47K | $23.73 | $106K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Harper Molly, Director | SSale | −15.5K | $23.20 | $360K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Harper Molly, Director | MExercise | +20.0K | $5.78 | $116K | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Tierney David S Director | MExercise | +1.41K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Thompson Tamar Director | MExercise | +1.41K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Sundaram Preethi Chief Strategy Officer | FTax | −1.67K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Sundaram Preethi, Chief Strategy Officer | MExercise | +6.86K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Miller Steve Chief Op. & Scientific Officer | MExercise | +11.9K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | MCENANY PATRICK J Director | MExercise | +3.53K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Harper Molly Director | MExercise | +1.41K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Elsbernd Brian Chief Compliance/Legal Officer | FTax | −2.78K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Elsbernd Brian, Chief Compliance/Legal Officer | MExercise | +7.07K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | DENKHAUS DONALD A Director | MExercise | +1.41K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Del Carmen Jeffrey Chief Commercial Officer | FTax | −2.49K | — | — | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Del Carmen Jeffrey, Chief Commercial Officer | MExercise | +8.04K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CPRX’s full analysis or the market-wide insider trading feed. The tabs above jump to CPRX’s other SEC data.
Source: SEC Form 4 filings for CPRX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.